Dr. K. Pavithran

Dr. K. Pavithran currently serves as Professor and Head of the Department of Medical Oncology and Hematology at Amrita Institute of Medical Sciences, Kochi. He took his MD in Internal Medicine from Calicut Medical College and DM in Medical Oncology from Kidwai Memorial Institute of Oncology, Bangalore. He is a Fellow of the Royal College of Physicians, London. He had his training in hematology from the Royal Hallamshire Hospital, Sheffield, United Kingdom and gained experience in bone-marrow transplantation from Fred Hutchinson Cancer Centre, Seattle, USA.
Dr. Pavithran is a member of many national (ISHTM, ISMPO, ISO, API, IMA, Indian Association of Cancer Research, ICON) and international organizations (American Society of Medical Oncology, European Society of Medical Oncology, International Medical Sciences Academy, International Association for the Study of Lung Cancer (IASLC).
He has presented many papers and delivered many lectures at various national and international conferences. He has participated in more than 35 clinical trials.
He is also the reviewer for Biomed Central Journals (www.biomedcentral.com), American Journal of Clinical Oncology, Supportive Oncology, Indian Journal of Cancer, Journal of Cancer Research and Experimental Oncology, Indian Journal of Medical & Pediatric Oncology, Journal of Association of Physicians of India, Indian Journal of Dermatology & Venereology, Indian Journal of Medical Sciences and Indian Journal of Hematology and Transfusion Medicine. He also serves in the editorial board of many national and international journals.

He has been awarded Fellowship by the World Federation of Haemophilia in 1993 and Indian College of Physicians in 2003. He is also a Fellow of International Medical Sciences Academy and a Fellow of the Royal College of Physicians, London.

He has to his credit numerous publications (80 papers in International Journals and 98 in National Journals). He has edited two books on cancer (Essentials of Clinical Oncology and A Companion to Essentials of Clinical Oncology) and has contributed more than 40 chapters in various books.

Publications 2021

• P. Viral, Dr. Pavithran K., Beena, K., Shaji, A., and Vijaykumar, D., “Ten-year survival outcome of breast cancer patients in India”, Journal of Carcinogenesis, vol. 20, no. 1, pp. 1 - 1, 2021.
• A. K. Paul, Jayamohanan, H., and Dr. Pavithran K., “Tazemetostat– A Drug review”, International Journal of Research in Pharmaceutical Sciences, vol. 12, no. 1, pp. 894-898, 2021.
• G. Gandham, Jayamohanan, H., Rajanbabu, A., and Dr. Pavithran K., “Metastatic endometrial carcinoma responsive to pembrolizumab”, International Journal of Molecular & Immuno Oncology , vol. 6, no. 1, pp. 50-53, 2021.
• P. Viral, Rajanbabu, A., Dr. Pavithran K., Chithrathara, K., Nair, I. R., Bhaskaran, R., Gangadharan, P., and Vijaykumar, D. K., “Long-term survival outcome of advanced epithelial ovarian cancer: A single institutional study.”, Indian J Cancer, 2021.
• A. A. Mehta, Shafi, T. M., Nambiar, A., and Dr. Pavithran K., “Diagnostic utility of medical thoracoscopy in T cell lymphoblastic lymphoma presenting with pleural effusion.”, Respir Med Case Rep, vol. 32, p. 101322, 2021.
• V. K. Srinivasalu, Subramaniam, N., Philip, A., Jose, W., and Dr. Pavithran K., “Triple intrathecal chemotherapy for leptomeningeal carcinomatosis in solid tumors: Treatment outcomes, response and their determinants.”, Indian J Cancer, vol. 58, no. 1, pp. 84-90, 2021.
• S. S. Kumar, Arun Philip, and Dr. Pavithran K., “Ripretinib: A narrative drug review”, Cancer Research, Statistics, and Treatment , vol. 4, no. 1, pp. 93-98, 2021.
• A. Damle, Sreenija, Y., Mathews, N. Rebecca, Nair, K., Philp, A., Dr. Pavithran K., and Paulose, R. Rachel, “Malignant Gastrointestinal Neuroectodermal Tumour-Case Report with Review of Literature.”, J Gastrointest Cancer, 2021.
• J. Thayath, Dr. Pavithran K., Nair, S. V., and Koyakutty, M., “Cancer nanomedicine developed from total human serum: a novel approach for making personalized nanomedicine.”, Nanomedicine (Lond), vol. 16, no. 12, pp. 997-1015, 2021.
• K. Sarada, Puthiyedath, R., Arun Philip, Greeshma C. Ravindran, and Dr. Pavithran K., “Prevalence of the use of traditional complementary and alternative medicine amongst cancer patients in a tertiary care center in Kerala, India”, Journal of Ayurveda and Integrative Medicine, 2021.

Publications 2020

• Kumar SS, Nazarudeen F, Rajanbabu A, Pavithran K. Isolated Splenic Metastasis from Ovarian Carcinoma. Indian J Gynecol Oncolog 2020; 18, 98. https://doi.org/10.1007/s40944-020-00446-z
• Divya GR, Jayamohanan H, Smitha NV, Anoop R, Nambiar A, Krishnakumar T, Pavithran K. Primary Neuroendocrine Carcinoma of the Larynx: A Case Report. Indian J Otolaryngol Head Neck Surg 2020. https://doi.org/10.1007/s12070-020-02060-z
• Hemakumar A, Pavithran K. Imatinib-induced haematuria necessitating drug discontinuation. Journal of Onco-Nephrology 2020. https://doi.org/10.1177/2399369320946760
• Bahl A, Talwar V, Sirohi B, Mehta P, Arya D, Shrivastava G, Dahiya A, Pavithran K. Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC). Front Oncol 2020;10:964. Published 2020 Jun 16. doi:10.3389/fonc.2020.00964
• Thomas S, Prasanna Thankappan A, Devi Padma U, Pavithran K. Therapeutic Drug Monitoring of Sorafenib in Hepatocellular Carcinoma Patients. Ther Drug Monit 2020 Apr;42(2):345-347.
• David E, Krishna R, Ramachandran L, Raghuram S, Philip A, Pavithran K. Pemetrexed-Associated Hyperpigemented Skin Rash. Am J Ther 2020 Feb 6. doi: 10.1097/MJT.0000000000001146.
• Indu RN, Athulya S, Pooja P, Pavithran K. Immunohistochemical Markers of Tumor Microenvironment as Prognostic Predictors in Diffuse Large B-Cell Lymphoma: Study from an Oncology Centre in South India. Asian J Oncology 2020. DOI: 10.1055/s-0040-1714305
• Kunheri B, Raj RV, Vijaykumar DK, Pavithran K. Impact of St. Gallen surrogate classification for intrinsic breast cancer sub-types on disease features, recurrence, and survival in South Indian patients. Indian J Cancer. 2020 Jan-Mar;57(1):49-54.

Clinical Trials-Ongoing

• A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum-Based Chemotherapy with Durvalumab in First-Line Stage IV Non-Small Cell Lung Cancer (ORION)
• A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy
• A Prospective, Randomized, Multicentre, Comparative, open-label, Parallel study to evaluate the Efficacy, Safety and Pharmacokinetics of Test-Trastuzumab Emtansine (ZRC-3256; Cadila Healthcare Ltd) and Reference-Trastuzumab Emtansine (Kadcyla®, a product of Roche) in HER2- Positive Metastatic Breast Cancer Patients.
• Reditux™ Registry to Compare Effectiveness, Safety, and Resource Utilization of Reditux™ v-s. the Reference Medicinal Product to Treat Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukaemia in Routine Clinical Practice.